论文部分内容阅读
该文研究的目的旨在评价重组干扰素(xIFN)治疗儿童慢性丙型肝炎(CHC)的效果。病人与方法12例CHC患儿均年龄8.37±4.96岁(18个月～15岁)。7例为男孩,2例各输1次血,10例感染途径不明。仪1例发病时有急性症状。治疗前平均随访2.88±2.31年(8个月～9年)。在此期间所有患儿血清丙氨酸转氨酸(ALT)均增高,自身抗体均阴性,乙肝表面抗原(HBsAg),乙肝核心(HBC)及人免疫缺陷病毒(HIV)抗体也均阴性,也排除了肝损害的其它原因。用ELISA法回顾性检测抗丙型肝炎病毒
The aim of this study was to evaluate the efficacy of recombinant IFN (xIFN) in the treatment of childhood chronic hepatitis C (CHC). Patients and Methods All 12 CHC children were 8.37 ± 4.96 years (18 months to 15 years old). Seven cases were boys, two cases each lost one blood and 10 cases were unknown. Instrument 1 case of acute symptoms. Before treatment, the average follow-up was 2.88 ± 2.31 years (8 months to 9 years). During this period all children with serum alanine aminotransferase (ALT) were increased, autoantibodies were negative, hepatitis B surface antigen (HBsAg), hepatitis B core (HBC) and human immunodeficiency virus (HIV) antibodies were also negative Ruled out other causes of liver damage. Anti-hepatitis C virus was retrospectively detected by ELISA